Lucid Diagnostics Inc. Common Stock (LUCD)

Price$1.30

Favorite Metrics

Price vs S&P 500 (26W)-0.05%

Price vs S&P 500 (4W)-9.49%

Market Capitalization$221.18M

All Metrics

Book Value / Share (Quarterly)$0.08

P/TBV (Annual)13.45x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)131.36%

Cash Flow / Share (Quarterly)$-0.36

Price vs S&P 500 (YTD)10.54%

Gross Margin (TTM)-41.76%

Net Profit Margin (TTM)-1232.68%

EPS (TTM)$-0.66

10-Day Avg Trading Volume0.87M

EPS Excl Extra (TTM)$-0.66

EPS (Annual)$-0.57

ROI (Annual)-166.05%

Gross Margin (Annual)-41.73%

Net Profit Margin (5Y Avg)-4969.40%

Cash / Share (Quarterly)$0.26

Revenue Growth QoQ (YoY)25.65%

ROA (Last FY)-143.43%

Revenue Growth TTM (YoY)8.28%

EBITD / Share (TTM)$-0.57

Operating Margin (TTM)-1077.75%

Cash Flow / Share (Annual)$-0.36

P/B Ratio20.23x

P/B Ratio (Quarterly)13.07x

Net Income / Employee (Annual)$-1

EV / Revenue (TTM)44.73x

Net Interest Coverage (TTM)-41.55x

ROA (TTM)-140.54%

EPS Incl Extra (Annual)$-0.57

Current Ratio (Annual)1.31x

Quick Ratio (Quarterly)1.27x

3-Month Avg Trading Volume1.13M

52-Week Price Return14.68%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.08

P/S Ratio (Annual)47.00x

Asset Turnover (Annual)0.12x

52-Week High$1.70

Operating Margin (5Y Avg)-4903.94%

EPS Excl Extra (Annual)$-0.57

26-Week Price Return8.70%

Quick Ratio (Annual)1.27x

13-Week Price Return0.81%

Total Debt / Equity (Annual)2.19x

Current Ratio (Quarterly)1.31x

Enterprise Value$210.478

Asset Turnover (TTM)0.11x

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1232.68%

Cash / Share (Annual)$0.26

3-Month Return Std Dev65.20%

Gross Margin (5Y Avg)-224.39%

Net Income / Employee (TTM)$-1

ROE (Last FY)-530.45%

Net Interest Coverage (Annual)-212.25x

EPS Basic Excl Extra (Annual)$-0.57

Receivables Turnover (TTM)13.68x

Total Debt / Equity (Quarterly)2.19x

EPS Incl Extra (TTM)$-0.66

Receivables Turnover (Annual)13.68x

ROI (TTM)-80.27%

P/S Ratio (TTM)47.00x

Pretax Margin (5Y Avg)-4969.40%

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$0.08

Price vs S&P 500 (52W)-20.42%

Year-to-Date Return14.68%

5-Day Price Return-2.34%

EPS Normalized (Annual)$-0.57

ROA (5Y Avg)-141.03%

Net Profit Margin (Annual)-1232.68%

Month-to-Date Return8.70%

Cash Flow / Share (TTM)$-1.34

EBITD / Share (Annual)$-0.56

Operating Margin (Annual)-1077.73%

EPS Basic Excl Extra (TTM)$-0.66

P/TBV (Quarterly)13.45x

P/B Ratio (Annual)13.07x

Inventory Turnover (TTM)19.22x

Pretax Margin (TTM)-1232.68%

Book Value / Share (Annual)$0.08

Price vs S&P 500 (13W)-2.06%

Beta1.32x

Revenue / Share (TTM)$0.04

ROE (TTM)-209.05%

52-Week Low$0.95

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

4.17

4.18

Industry Peers — Surgical & Medical Instruments(108)

Symbol	P/S Ratio (TTM)	Revenue Growth (5Y)	Gross Margin (TTM)	Operating Margin (TTM)	Price
LUCDLucid Diagnostics Inc. Common Stock	47.00x	—	-41.76%	-1077.75%	$1.30
SYKStryker Corporation	5.17x	11.84%	64.57%	19.43%	$338.34
BSXBoston Scientific Corp.	4.58x	15.16%	69.01%	18.00%	$60.99
MMM3M Company	3.21x	-4.97%	39.92%	18.55%	$151.40
MDLNMedline Inc. Class A common stock	2.20x	—	26.44%	7.78%	$48.26
BDXBecton, Dickinson and Co.	2.06x	6.32%	46.42%	12.15%	$158.64
RMDResMed Inc.	6.07x	11.72%	60.85%	33.70%	$226.14
DXCMDexCom, Inc.	5.33x	19.33%	62.09%	19.56%	$64.62
WSTWest Pharmaceutical Services, Inc.	6.29x	7.44%	35.91%	19.03%	$278.00
PODDInsulet Corporation	5.19x	24.53%	71.63%	12.92%	$200.87
PENPenumbra, Inc.	9.24x	20.16%	67.14%	13.48%	$329.71

About

Lucid Diagnostics is a commercial-stage company developing diagnostic tools for patients with gastroesophageal reflux disease (GERD) at risk of esophageal cancer. Its products, EsoCheck and EsoGuard, enable detection of precancerous changes in the esophagus, addressing an unmet clinical need in cancer prevention. The company targets a significant market opportunity among millions of GERD patients vulnerable to esophageal adenocarcinoma.